User: vishwas Topic: IP
Category: drugs :: everywhere
Last updated: Jan 03 2018 17:02 IST RSS 2.0
 
1 to 20 of 5,218    
Indian pharma growth likely to be moderate: ICRA 3.1.2018 Sify Finance
[India], Jan 3 (ANI): The growth trajectory for Indian pharmaceutical industry is likely to be moderate, according to credit rating agency ICRA.
Also found in: [+]
Succession doubts cloud Apotex future after billionaire owner's death 22.12.2017 Sify Finance
By Matt Scuffham
Also found in: [+]
Morepen Gets US FDA clearance for its Bulk Drug Montelukast Sodium 20.12.2017 Sify Finance
[India], Dec 20 (ANI-NewsVoir): The United States Food and Drug Administration (USFDA) has cleared Montelukast Sodium, a bulk drug / API manufactured by Morepen Laboratories Ltd., for sale in the
Also found in: [+]
BRIEF-India's Lincoln Pharmaceuticals Gets Patent For 'Antimalarial Drug' 19.12.2017 Sify Finance
Dec 19 (Reuters) - Lincoln Pharmaceuticals Ltd:
Also found in: [+]
After 15 years, Ranjit Shahani steps down as Novartis MD 14.11.2017 Rediff: Business
The face of MNC drug firms in India and champion of IPR protection, he oversaw the Swiss giant's India expansion, its forays into new therapies and setting up of its global service centre in Hyderabad
Also found in: [+]
Base Erosion and Profit Shifting guidelines stump MNCs 14.10.2017 ET: Pharma
Under BEPS, multinationals will be required to declare details of revenues earned, taxes paid, employees hired, supply chain management in every country they operate in.
Also found in: [+]
Activists challenge Pneumonia vaccine patent in Delhi High Court 14.10.2017 DNA: Mumbai
Activists have challenged the patent claims of pharma giant Pfizer on a vaccine for pneumonia in the Delhi High Court. Médecins Sans Frontières or Doctors Without Borders (India) has filed a petition to overturn the patent granted earlier this year, on August 13 by the Indian Patent Office to Pfizer. “India has dashed hopes for improved access to an affordable PCV13 when it granted a patent to Pfizer for its PCV 13 product, marketed as Prevnar13, which will expire only in 2026,” a statement issued by MSF said. In the petition, MSF argues that in August 2017, the Delhi Patent Office erroneously granted a patent to Pfizer by disregarding the evidence MSF produced indicating that the pharmaceutical giant’s claim to a patent was spurious. MSF argued that the mere addition of serotypes to the already established 7-valent vaccine did not involve a technical advancement – it was merely a tactic to preserve Pfizer’s monopoly for many more years. The decision also has broader implications, as it indicates a ...
Also found in: [+]
MSF drags govt to Delhi HC over Pfizer's pneumonia vaccine patent 14.10.2017 ET: Pharma
The Indian patent office granted Pfizer a patent for its vaccine PCV13 (13-valent pneumococcal conjugate vaccine), sold here under the brand ‘Prevenar13’ for over 10 years.
Also found in: [+]
Suven Life Sciences shares pare some gains after rising 10% 10.10.2017 Sify Finance
Also found in: [+]
Suven Life gets patent from New Zealand for neurological drug 10.10.2017 ET: Pharma
Suven Life said it has been granted "one product patent from New Zealand corresponding to the NCEs for the treatment of disorders associated with neuro-degenerative diseases".
Also found in: [+]
Mylan surges, Teva slumps after FDA approves Copaxone copy 5.10.2017 Sify Finance
By Michael Erman and Divya Grover
Also found in: [+]
U.S. senators want probe of Allergan transfer deal with tribe: letter 28.9.2017 Sify Finance
By Jan Wolfe
Also found in: [+]
U.S. STOCKS ON THE MOVE-Oracle, Genworth, Airlines, Carnival Corp, Mirati Therapeutics 15.9.2017 TOI: Intl Business
MARKETS-USA-STOCKS/PULSE:BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Genworth, Airlines, Carnival Corp, Mirati Therapeutics
Also found in: [+]
Indivior files patent lawsuits against generic Suboxone rivals 15.9.2017 Sify Finance
REUTERS - Indivior said on Friday its U.S. subsidiary has filed patent lawsuits against firms seeking approval for generic versions of its opioid addiction treatment Suboxone, which generates 80
Also found in: [+]
Challenge of Allergan tribal patent deal in uncharted legal territory 15.9.2017 TOI: Intl Business
ALLERGAN-PATENTS/ (CORRECTED):REFILE-Challenge of Allergan tribal patent deal in uncharted legal territory
Also found in: [+]
Pharma companies inflating R&D costs? 14.9.2017 ET: Pharma
Though the study was restricted to cancer drugs, it raises questions about whether R&D costs are much lower than claimed by the pharma industry and if so whether patent terms need to be so long.
Also found in: [+]
Pharma companies inflating R&D costs? 14.9.2017 TOI: India
Also found in: [+]
Mylan says Allergan misusing tribal sovereignty in patent dispute 13.9.2017 TOI: Intl Business
ALLERGAN-PATENTS/MYLAN:Mylan says Allergan misusing tribal sovereignty in patent dispute
Also found in: [+]
U.S. tribal patent deal could have big impact on generic drug market 12.9.2017 Sify Finance
By Jan Wolfe
Also found in: [+]
U.S. tribal patent deal could have big impact on generic drug market 12.9.2017 TOI: Intl Business
ALLERGAN-PATENTS/MOHAWK:U.S. tribal patent deal could have big impact on generic drug market
Also found in: [+]
1 to 20 of 5,218